Reduction in advanced glycation end products by ACE inhibitor in diabetic cardiomyopathy model

Yao Chang Wang, Chiz Tzung Chang, Pao Shen Tsu, Chi Hsiao Yeh, Wan Chun Chiu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Advanced glycation end-products (AGEs) due to hyperglycemia have been reported with diabetic complications. The effect of angiotensin converting enzyme (ACE) inhibition on the formation of AGEs and oxidative stress in the myocardium was explored. Methods: Streptozocin-induced diabetic rats were randomized to three groups including untreated, treated with ACE inhibitor captopril, and treated with aminoguanidine for 24 weeks with non-diabetic rats as control. Results: At study end, elevations of blood pressure, heart to body weight ratio, and brain natriuretic peptide levels were found in diabetic rats, indicating cardiac hypertrophy and dysfunction. Accumulation of myocardial AGEs/ receptor of AGEs (RAGEs), as determined by immunohistochemistry and Western blots were increased in diabetic animals, which were attenuated by both captopril and aminoguanidine. Staining of nitrotyrosine and 8- hydroxydeaminoguanosine, markers of oxidative stress, also increased in diabetic rats and was attenuated by both captopril and aminoguanidine treatment. The myocardial pentosidine, a marker of AGEs, increased in diabetic rats but was not significantly affected by either treatment. Conclusion: This study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic hearts that may be linked through oxidative stress.

Original languageEnglish
Pages (from-to)29-37
Number of pages9
JournalAsian Biomedicine
Volume7
Issue number1
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Diabetic Cardiomyopathies
Advanced Glycosylation End Products
Angiotensin-Converting Enzyme Inhibitors
Rats
Oxidative stress
Captopril
Oxidative Stress
Enzyme inhibition
Brain Natriuretic Peptide
Blood pressure
Angiotensins
Cardiomegaly
Peptidyl-Dipeptidase A
Diabetes Complications
Renin-Angiotensin System
Streptozocin
Renin
Hyperglycemia
Myocardium
Animals

Keywords

  • ACE inhibitor
  • Advanced glycation end products
  • Aminoguanidine
  • Diabetic mellitus
  • Oxidative stress.

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Reduction in advanced glycation end products by ACE inhibitor in diabetic cardiomyopathy model. / Wang, Yao Chang; Chang, Chiz Tzung; Tsu, Pao Shen; Yeh, Chi Hsiao; Chiu, Wan Chun.

In: Asian Biomedicine, Vol. 7, No. 1, 02.2013, p. 29-37.

Research output: Contribution to journalArticle

Wang, Yao Chang ; Chang, Chiz Tzung ; Tsu, Pao Shen ; Yeh, Chi Hsiao ; Chiu, Wan Chun. / Reduction in advanced glycation end products by ACE inhibitor in diabetic cardiomyopathy model. In: Asian Biomedicine. 2013 ; Vol. 7, No. 1. pp. 29-37.
@article{54504e8e24ee4977ae1fef0197810720,
title = "Reduction in advanced glycation end products by ACE inhibitor in diabetic cardiomyopathy model",
abstract = "Background: Advanced glycation end-products (AGEs) due to hyperglycemia have been reported with diabetic complications. The effect of angiotensin converting enzyme (ACE) inhibition on the formation of AGEs and oxidative stress in the myocardium was explored. Methods: Streptozocin-induced diabetic rats were randomized to three groups including untreated, treated with ACE inhibitor captopril, and treated with aminoguanidine for 24 weeks with non-diabetic rats as control. Results: At study end, elevations of blood pressure, heart to body weight ratio, and brain natriuretic peptide levels were found in diabetic rats, indicating cardiac hypertrophy and dysfunction. Accumulation of myocardial AGEs/ receptor of AGEs (RAGEs), as determined by immunohistochemistry and Western blots were increased in diabetic animals, which were attenuated by both captopril and aminoguanidine. Staining of nitrotyrosine and 8- hydroxydeaminoguanosine, markers of oxidative stress, also increased in diabetic rats and was attenuated by both captopril and aminoguanidine treatment. The myocardial pentosidine, a marker of AGEs, increased in diabetic rats but was not significantly affected by either treatment. Conclusion: This study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic hearts that may be linked through oxidative stress.",
keywords = "ACE inhibitor, Advanced glycation end products, Aminoguanidine, Diabetic mellitus, Oxidative stress.",
author = "Wang, {Yao Chang} and Chang, {Chiz Tzung} and Tsu, {Pao Shen} and Yeh, {Chi Hsiao} and Chiu, {Wan Chun}",
year = "2013",
month = "2",
doi = "10.5372/1905-7415.0701.148",
language = "English",
volume = "7",
pages = "29--37",
journal = "Asian Biomedicine",
issn = "1905-7415",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Reduction in advanced glycation end products by ACE inhibitor in diabetic cardiomyopathy model

AU - Wang, Yao Chang

AU - Chang, Chiz Tzung

AU - Tsu, Pao Shen

AU - Yeh, Chi Hsiao

AU - Chiu, Wan Chun

PY - 2013/2

Y1 - 2013/2

N2 - Background: Advanced glycation end-products (AGEs) due to hyperglycemia have been reported with diabetic complications. The effect of angiotensin converting enzyme (ACE) inhibition on the formation of AGEs and oxidative stress in the myocardium was explored. Methods: Streptozocin-induced diabetic rats were randomized to three groups including untreated, treated with ACE inhibitor captopril, and treated with aminoguanidine for 24 weeks with non-diabetic rats as control. Results: At study end, elevations of blood pressure, heart to body weight ratio, and brain natriuretic peptide levels were found in diabetic rats, indicating cardiac hypertrophy and dysfunction. Accumulation of myocardial AGEs/ receptor of AGEs (RAGEs), as determined by immunohistochemistry and Western blots were increased in diabetic animals, which were attenuated by both captopril and aminoguanidine. Staining of nitrotyrosine and 8- hydroxydeaminoguanosine, markers of oxidative stress, also increased in diabetic rats and was attenuated by both captopril and aminoguanidine treatment. The myocardial pentosidine, a marker of AGEs, increased in diabetic rats but was not significantly affected by either treatment. Conclusion: This study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic hearts that may be linked through oxidative stress.

AB - Background: Advanced glycation end-products (AGEs) due to hyperglycemia have been reported with diabetic complications. The effect of angiotensin converting enzyme (ACE) inhibition on the formation of AGEs and oxidative stress in the myocardium was explored. Methods: Streptozocin-induced diabetic rats were randomized to three groups including untreated, treated with ACE inhibitor captopril, and treated with aminoguanidine for 24 weeks with non-diabetic rats as control. Results: At study end, elevations of blood pressure, heart to body weight ratio, and brain natriuretic peptide levels were found in diabetic rats, indicating cardiac hypertrophy and dysfunction. Accumulation of myocardial AGEs/ receptor of AGEs (RAGEs), as determined by immunohistochemistry and Western blots were increased in diabetic animals, which were attenuated by both captopril and aminoguanidine. Staining of nitrotyrosine and 8- hydroxydeaminoguanosine, markers of oxidative stress, also increased in diabetic rats and was attenuated by both captopril and aminoguanidine treatment. The myocardial pentosidine, a marker of AGEs, increased in diabetic rats but was not significantly affected by either treatment. Conclusion: This study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic hearts that may be linked through oxidative stress.

KW - ACE inhibitor

KW - Advanced glycation end products

KW - Aminoguanidine

KW - Diabetic mellitus

KW - Oxidative stress.

UR - http://www.scopus.com/inward/record.url?scp=84875533968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875533968&partnerID=8YFLogxK

U2 - 10.5372/1905-7415.0701.148

DO - 10.5372/1905-7415.0701.148

M3 - Article

VL - 7

SP - 29

EP - 37

JO - Asian Biomedicine

JF - Asian Biomedicine

SN - 1905-7415

IS - 1

ER -